Publikationen 2016

Albers P.
Behandlung des metastasierten Prostatakarzinoms.
Drug Res (Stuttg). 2016 Nov;66(S 01):S35. German.
PubMed PMID: 27806404.

Arsov C, Rabenalt R, Quentin M, Hiester A, Blondin D, Albers P, Antoch G, Schimmöller L.
Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial.
World J Urol. 2016 Feb;34(2):215-20.
doi: 10.1007/s00345-015-1612-6. PubMed PMID: 26055645.

Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX.
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics. 2016 Oct 25;17(1):829.
PubMed PMID: 27782819; PubMed Central PMCID: PMC5080754.

Esch LH, Fahlbusch M, Albers P, Hautzel H, Müller-Mattheis V.
11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.
BJU Int. 2016 Nov 8.
doi: 10.1111/bju.13706. [Epub ahead of print] PubMed PMID: 27860163.

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A,  Flechon A, Boyle H, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Sava T, Winquist EW, De Giorgi U, Aparicio J, Sweeney CJ, Cohn Cedermark G, Beyer J, Powles T. Brain
Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.
J Clin Oncol. 2016 Feb 1;34(4):345-51.
doi: 10.1200/JCO.2015.62.7000. PubMed PMID: 26460295; PubMed Central PMCID: PMC5070579.

Flechtner HH, Fischer F, Albers P, Hartmann M, Siener R; German Testicular Cancer Study Group..
Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Eur Urol. 2016  Mar;69(3):518-25.
doi: 10.1016/j.eururo.2015.11.007. PubMed PMID: 26620368.

Friedersdorff F, Kothmann L, Manus P, Roigas J, Kempkensteffen C, Magheli A, Busch J, Liefeldt L, Giessing M, Deger S, Schostak M, Miller K, Fuller TF.
Long-Term Donor Outcomes after Pure Laparoscopic versus Open Living Donor Nephrectomy: Focus on Pregnancy Rates, Hypertension and Quality of Life.
Urol Int. 2016;97(4):450-456.
PubMed PMID: 27577572.

Füssel S, Kramer MW, Stöhr R, Olbert P, Nawroth R, Schulz WA.
[Report on the 5th symposium of the German research network bladder carcinoma].
Urologe A. 2016  May;55(5):663-4.
doi: 10.1007/s00120-016-0100-y. German. PubMed PMID: 27138635.

Haldrup C, Lynnerup AS, Storebjerg TM, Vang S, Wild P, Visakorpi T, Arsov C, Schulz WA, Lindberg J, Grönberg H, Egevad L, Borre M, Ørntoft TF, Høyer S, Sørensen KD.
Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
Mol Oncol. 2016 Jun;10(6):825-37.
doi: 10.1016/j.molonc.2016.02.001. PubMed PMID: 26905753.

Höhn A, Krüger K, Skowron MA, Bormann S, Schumacher L, Schulz WA, Hoffmann MJ, Niegisch G, Fritz G.
Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Oncotarget. 2016 Jul 5;7(27):41320-41335.
doi: 10.18632/oncotarget.9321. PubMed PMID: 27191498; PubMed Central PMCID: PMC5173062.

Hoffmann MJ, Koutsogiannouli E, Skowron MA, Pinkerneil M, Niegisch G, Brandt A, Stepanow S, Rieder H, Schulz WA.
The New Immortalized Uroepithelial Cell Line  HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors.
Bladder Cancer. 2016 Oct 27;2(4):449-463.
doi: 10.3233/BLC-160065. PubMed PMID: 28035326; PubMed Central PMCID: PMC5181672.

Kögel AM, Dinkel A, Marten-Mittag B, Baron J, Albers P, Arsov C, Hadaschik B,  Hohenfellner M, Imkamp F, Kuczyk M, Gschwend JE, Herkommer K.
[Self-concept and erectile dysfunction in 45-year-old men : Results of a corollary study of the PROBASE trial].
Urologe A. 2016 Oct;55(10):1321-1328. German.
PubMed PMID: 27138634.

Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S.
Quality assessment in prostate cancer centers certified by the German Cancer Society.
World J Urol. 2016 May;34(5):665-72.
doi: 10.1007/s00345-015-1688-z. PubMed PMID: 26391484.

Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ.
Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.
Clin Genitourin Cancer. 2016 Aug;14(4):331-40.
doi: 10.1016/j.clgc.2015.10.005. PubMed PMID: 26589729.

Lorch A, Beyer J.
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
World J Urol. 2016 Sep 27.
[Epub ahead of print] PubMed PMID: 27678272.

Lusch A, Albers P.
Residual tumor resection (RTR).
World J Urol. 2016 Dec 21.
doi: 10.1007/s00345-016-1984-2.
[Epub ahead of print] PubMed PMID: 28004146.

Lusch A, Fujimoto S, Findeiss LK, Okhunov Z, McDougall EM, Landman J.
Anthropometric Renal Anatomic Alterations Between Supine and Prone Positions in Percutaneous Renal Ablation for Renal Cortical Neoplasms.
J Endourol. 2016 Feb;30(2):165-9.
doi: 10.1089/end.2015.0373. PubMed PMID: 26414388.

Lusch A, Heidari E, Okhunov Z, Osann K, Landman J.
Evaluation of Contemporary  Holmium Laser Fibers for Performance Characteristics.
J Endourol. 2016 May;30(5):567-73.
doi: 10.1089/end.2015.0600. PubMed PMID: 26908224.

Miller K, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, Mickisch G, Pfister D, Schwentner C, Suttmann H, Zastrow S.
[Metastatic castration-resistant  prostate cancer : Clinical data, new treatment options and therapy monitoring].
Urologe A. 2016 Sep;55(9):1206-12.
doi: 10.1007/s00120-016-0176-4. German. PubMed PMID: 27411995.

Nakhaei-Rad S, Nakhaeizadeh H, Götze S, Kordes C, Sawitza I, Hoffmann MJ, Franke M, Schulz WA, Scheller J, Piekorz RP, Häussinger D, Ahmadian MR.
The Role  of Embryonic Stem Cell-expressed RAS (ERAS) in the Maintenance of Quiescent Hepatic Stellate Cells.
J Biol Chem. 2016 Apr 15;291(16):8399-413.
doi: 10.1074/jbc.M115.700088. PubMed PMID: 26884329; PubMed Central PMCID: PMC4861415.

Nasrollahzadeh-Khakiani M, Emadi-Baygi M, Schulz WA, Nikpour P.
Long noncoding RNAs in gastric cancer carcinogenesis and metastasis.
Brief Funct Genomics. 2016  Apr 27.
pii: elw011. [Epub ahead of print] PubMed PMID: 27122631.

Niegisch G, Retz M, Siener R, Albers P.
Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy.
Urol Oncol. 2016 Jun;34(6):256.e15-21.
doi: 10.1016/j.urolonc.2016.02.002. PubMed PMID: 26944451.

Rexer H, Retz M, Albers P.
[Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation  in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO].
Urologe A. 2016 Nov;55(11):1491-1493. German.
PubMed PMID: 27714413.

Ohlmann CH, Stöckle M, Albers P, Schmidberger H, Härter M, Kristiansen G, Martus P, Wellek S, Bussar-Maatz R, Wiegel T.
[PREFERE - Study on the rise].
Urologe A. 2016 Mar;55(3):313-7.
doi: 10.1007/s00120-016-0047-z. German. PubMed PMID: 26908120

Pérez-Lanzac A, Parra-Serván P, León-Delgado C, Okhunov Z, Lusch A, Álvarez-Ossorio JL.
Combination of extracorporeal lithotripsy and flexible ureterorenoscopy optimize renal lithiasis therapy.
Actas Urol Esp. 2016 Sep 5. pii: S0210-4806(16)30122-X.
doi: 10.1016/j.acuro.2016.08.002. [Epub ahead of print] English, Spanish. PubMed PMID: 27609350.

Pinkerneil M, Hoffmann MJ, Deenen R, Köhrer K, Arent T, Schulz WA, Niegisch G.
Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
Mol Cancer Ther. 2016 Feb;15(2):299-312.
doi: 10.1158/1535-7163.MCT-15-0618. PubMed PMID: 26772204.

Pinkerneil M, Hoffmann MJ, Kohlhof H, Schulz WA, Niegisch G.
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
Target Oncol. 2016 Dec;11(6):783-798.
PubMed PMID: 27250763; PubMed Central PMCID: PMC5153417.

Rabenalt R.
[Not Available].
Aktuelle Urol. 2016 Sep;47(5):415-24.
doi: 10.1055/s-0042-108781. German. PubMed PMID: 27680193.

Rezaei M, Emadi-Baygi M, Hoffmann MJ, Schulz WA, Nikpour P.
Altered expression of LINC-ROR in cancer cell lines and tissues.
Tumour Biol. 2016 Feb;37(2):1763-9.
doi: 10.1007/s13277-015-3933-x. PubMed PMID: 26314857.

Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, Bellmunt J,  Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI;
Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.. Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder  Cancer.
Bladder Cancer. 2016 Oct 27;2(4):405-413.
doi: 10.3233/BLC-160072. PubMed PMID: 28035321; PubMed Central PMCID: PMC5181658. 

Schimmöller L, Blondin D, Arsov C, Rabenalt R, Albers P, Antoch G, Quentin M.
MRI-Guided In-Bore Biopsy: Differences Between Prostate Cancer Detection and Localization in Primary and Secondary Biopsy Settings.
AJR Am J Roentgenol. 2016  Jan;206(1):92-9.
doi: 10.2214/AJR.15.14579. PubMed PMID: 26700339.

Schimmöller L, Quentin M, Blondin D, Dietzel F, Hiester A, Schleich C, Thomas  C, Rabenalt R, Gabbert HE, Albers P, Antoch G, Arsov C.
Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?
Eur Radiol. 2016 Nov;26(11):3858-3864.
PubMed PMID: 26920391.

Schulz WA, Goering W.
DNA methylation in urothelial carcinoma.
Epigenomics. 2016 Oct;8(10):1415-1428.
PubMed PMID: 27624974.

Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C.
Efficacy and safety of gemcitabine,  oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Urol Oncol. 2016 Apr;34(4):167.e21-8.
doi: 10.1016/j.urolonc.2015.11.007. PubMed PMID: 26699830.

Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, Necchi A,  Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J.
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr;69(4):634-41.
doi: 10.1016/j.eururo.2015.07.042. PubMed PMID: 26264159.

Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A,  Giannatempo P, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J.
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2016 Dec;14(6):494-498.
doi: 10.1016/j.clgc.2016.05.001. PubMed PMID: 27262369.

Zi X, Lusch A, Blair CA, Okhunov Z, Yokoyama NN, Liu S, Baker M, Huynh V, Landman J.
Effect of perineoplasm perinephric adipose tissues on migration of clear cell renal cell carcinoma cells: a potential role of WNT signaling.
Oncotarget. 2016 Aug 16;7(33):53277-53288.
doi: 10.18632/oncotarget.10467. PubMed PMID: 27409168.